Gene therapy of muscular dystrophy

被引:85
作者
Chamberlain, JS [1 ]
机构
[1] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1093/hmg/11.20.2355
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Development of gene therapy for the muscular dystrophies represents a daunting challenge requiring significant advances in our knowledge of the defective genes, muscle promoters, viral vectors, immune system surveillance and methods for systemic delivery of vectors. However, tremendous progress has been made in developing improved viral vectors and avoiding immune reactions against gene transfer. This review summarizes recent progress and highlights problems that must be solved before an effective treatment is available.
引用
收藏
页码:2355 / 2362
页数:8
相关论文
共 115 条
  • [41] Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector
    Greelish, JP
    Su, LT
    Lankford, EB
    Burkman, JM
    Chen, HY
    Konig, SK
    Mercier, IM
    Desjardins, PR
    Mitchell, MA
    Zheng, XG
    Leferovich, J
    Gao, GP
    Balice-Gordon, RJ
    Wilson, JM
    Stedman, HH
    [J]. NATURE MEDICINE, 1999, 5 (04) : 439 - 443
  • [42] Combinatorial blockade of calcineurin and CD28 signaling facilitates primary and secondary therapeutic gene transfer by adenovirus vectors in dystrophic (mdx) mouse muscles
    Guibinga, GH
    Lochmuller, H
    Massie, B
    Nalbantoglu, J
    Karpati, G
    Petrof, BJ
    [J]. JOURNAL OF VIROLOGY, 1998, 72 (06) : 4601 - 4609
  • [43] Dystrophin expression in the mdx mouse restored by stem cell transplantation
    Gussoni, E
    Soneoka, Y
    Strickland, CD
    Buzney, EA
    Khan, MK
    Flint, AF
    Kunkel, LM
    Mulligan, RC
    [J]. NATURE, 1999, 401 (6751) : 390 - 394
  • [44] Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy
    Harper, SQ
    Hauser, MA
    DelloRusso, C
    Duan, DS
    Crawford, RW
    Phelps, SF
    Harper, HA
    Robinson, AS
    Engelhardt, JF
    Brooks, SV
    Chamberlain, JS
    [J]. NATURE MEDICINE, 2002, 8 (03) : 253 - 261
  • [45] Hartigan-O'Connor D, 2000, MICROSC RES TECHNIQ, V48, P223, DOI 10.1002/(SICI)1097-0029(20000201/15)48:3/4<223::AID-JEMT10>3.0.CO
  • [46] 2-L
  • [47] Hartigan-O'Connor D, 2002, METHOD ENZYMOL, V346, P224
  • [48] Immune evasion by muscle-specific gene expression in dystrophic muscle
    Hartigan-O'Connor, D
    Kirk, CJ
    Crawford, R
    Mulé, JJ
    Chamberlain, JS
    [J]. MOLECULAR THERAPY, 2001, 4 (06) : 525 - 533
  • [49] Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors
    Hauser, MA
    Robinson, A
    Hartigan-O'Connor, D
    Williams-Gregory, D
    Buskin, JN
    Apone, S
    Kirk, CJ
    Hardy, S
    Hauschka, SD
    Chamberlain, JS
    [J]. MOLECULAR THERAPY, 2000, 2 (01) : 16 - 25
  • [50] MUTATIONS IN THE LAMININ ALPHA-2-CHAIN GENE (LAMA2) CAUSE MEROSIN-DEFICIENT CONGENITAL MUSCULAR-DYSTROPHY
    HELBLINGLECLERC, A
    ZHANG, X
    TOPALOGLU, H
    CRUAUD, C
    TESSON, F
    WEISSENBACH, J
    TOME, FMS
    SCHWARTZ, K
    FARDEAU, M
    TRYGGVASON, K
    GUICHENEY, P
    [J]. NATURE GENETICS, 1995, 11 (02) : 216 - 218